Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Senaparib by IMPACT Therapeutics for Ovarian Cancer: Likelihood of Approval
Senaparib is under clinical development by IMPACT Therapeutics and currently in Phase III for Ovarian Cancer. According to GlobalData, Phase...
Data Insights
Senaparib by IMPACT Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Senaparib is under clinical development by IMPACT Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...